BOSTON, May 13, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC) today announced that it will present additional results from the Phase 2b trial evaluating RTB101 (dactolisib), an oral, selective, and potent inhibitor of target of rapamycin complex 1 (TORC1), in an oral presentation entitled “Oral TORC1 Inhibitor Dactolisib Enhances Immune Function and Reduces the Incidence of Respiratory Tract Infections (RTIs) in Elderly Subjects with Asthma” during the American Thoracic Society (ATS) International Conference in Dallas, Texas from May 17-22, 2019 (abstract #A2623).
“RTIs are one of the most common triggers of asthma exacerbations and are caused by many different kinds of viruses, most of which lack current treatments,” said Joan Mannick, MD, Chief Medical Officer of resTORbio. “Preventing RTIs is of particular importance in asthmatics who are age 65 years and older. Asthma exacerbations are associated with a 5-fold increased risk of overall mortality in older as compared to younger adults with asthma. We look forward to presenting findings from our Phase 2b clinical trial in which the small molecule TORC1 inhibitor RTB101 was observed to decrease the incidence of RTIs caused by multiple different viruses in asthma patients age 65 and older.”
Following are details for the presentation:
|Session: ||B15 – Immunotherapy for Lung Disease |
|Presentation Title:||A2623 - Oral TORC1 Inhibitor Dactolisib Enhances Immune Function and Reduces the Incidence of Respiratory Tract Infections in Elderly Subjects with Asthma|
|Presenter:||Joan Mannick, MD, Co-Founder, Chief Medical Officer, Board of Directors, resTORbio|
|Date/Time:||May 20, 2019, 9:45 AM - 10:00 AM CDT|
|Room:||Room C146 (Level 1), KBHCCD|
About Respiratory Tract Infections in the Elderly
As part of the aging process, the immune system weakens and becomes less effective at detecting and fighting infections such as RTIs. As a result, RTIs are more likely to be of greater severity, prolonged duration, and are more likely to be associated with medical complications in people age 65 years and older as compared to younger adults. In the U.S., RTIs are the fourth leading cause of hospitalization and seventh leading cause of death in people aged 65 and older. Given that RTIs are caused by many different types of viruses, most of which lack effective therapies, there remains a significant unmet medical need for an immunotherapy that enhances the ability of the immune system to fight multiple viruses to reduce illness associated with RTIs in the elderly.
RTB101 is an oral, selective, and potent TORC1 inhibitor product candidate. TORC1 inhibition has been shown to be of therapeutic benefit in multiple aging-related conditions in preclinical species including immunosenescence (aging-related decline in immune function). In two Phase 2 clinical trials enrolling over 900 elderly people, RTB101 was observed to improve immune function by upregulation of antiviral gene expression and to reduce the incidence of RTIs.
resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases. resTORbio’s lead program selectively inhibits TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular and central nervous systems. Learn more about resTORbio, Inc. at www.resTORbio.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding our future plans to develop RTB101 alone or in combination with rapalogs, such as everolimus or sirolimus, including the therapeutic potential and clinical benefits thereof and the potential patient populations that may be addressed by our product candidates, our ongoing and future clinical trials for RTB101, including the timing of the initiation and anticipated results of these trials, the intended regulatory path for our product candidates and interactions with regulatory authorities, and our ability to replicate results achieved in our clinical trials in any future trials, constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions.
Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our planned Phase 3 clinical trials in RTIs and/or development of RTB101, either alone or in combination with a rapalog, such as everolimus or sirolimus; our ability to successfully demonstrate the efficacy and safety of our lead product candidate; the clinical results for our lead product candidate which may not support further development of additional indications; uncertainties related to the results of our clinical trials predictive of future results in connection with future trials, including our Phase 3 clinical trials; the timing and outcome of our planned interactions with regulatory authorities; and obtaining, maintaining and protecting our intellectual property; as well as those risks more fully discussed in the section entitled “Risk Factors” in the Annual Report on Form 10-K filed by resTORbio, Inc. with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing its views as of any subsequent date. resTORbio explicitly disclaims any obligation to update any forward-looking statements.